Listed

Nutex Health Inc.: Form 10-Q for the period ended Mar 31, 2017

Filed with the SEC on May 22, 2017 and accepted by EDGAR at May 22, 2017, 14:04 ET.

Share

Management's discussion and analysis

As filed, 12,125 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

of Operations

FORWARD LOOKING STATEMENTS

This Form 10-Q includes “forward-looking statements” within the meaning of

Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

Exchange Act of 1934, as amended. All statements, other than statements of historical

facts, included or incorporated by reference in this Form 10-Q which address activities,

events or developments that the Company expects or anticipates will or may occur in the

future, including such things as future capital expenditures (including the amount and

nature thereof), finding suitable merger or acquisition candidates, expansion and growth of

the Company’s business and operations, and other such matters are forward-looking

statements. These statements are based on certain assumptions and analyses made by the

Company in light of its experience and its perception of historical trends, current conditions

and expected future developments as well as other factors it believes are appropriate in the

circumstances.

Investors are cautioned that any such forward-looking statements are not

guarantees of future performance and involve significant risks and uncertainties, and that

actual results may differ materially from those projected in the forward-looking statements.

Factors that could adversely affect actual results and performance include, among others,

potential fluctuations in quarterly operating results and expenses, government regulation,

technology change and competition. Consequently, all of the forward-looking statements

made in this Form 10-Q are qualified by these cautionary statements and there can be no

assurance that the actual results or developments anticipated by the Company will be

realized or, even if substantially realized, that they will have the expected consequence to

or effects on the Company or its business or operations. The Company assumes no

obligations to update any such forward-looking statements.

INTRODUCTION

iGambit is a company focused on the medical technology markets. Our primary

focus is the expansion of our newly acquired medical technology business HealthDatix Inc.

HealthDatix is an end to end Software-as-a-Service solution that manages, reports,

and analyzes critical data, enabling healthcare organizations to deliver positive patient

outcomes. We offer a fully-hosted cloud service for healthcare providers to conduct the

Medicare Annual Wellness Visit (AWV) program to their Medicare patients providing the

patient with a 5-10 year Personalized Preventive Plan and physician reports that meet all

Medicare audit requirements. The AWV is a program that allows a physician to identify

those patients that have 2+ chronic conditions that require additional screening and

management.

Assets. At March 31, 2017, we had $1,722,838 in total assets, compared to

$510,835 at December 31, 2016. The increase in total assets was primarily due to the

increase in cash and the increase in intangible assets from the acquisition of our

HealthDatix subsidiary.

Liabilities. At March 31, 2017, our total liabilities were $6,677,714 compared to

$6,380,260 at December 31, 2016. Our current liabilities at March 31, 2017 consisted of

accounts payable and accrued expenses of $374,371, accrued interest on notes payable of

$1,801, amounts due to related parties of $1,000, notes payable of $60,500, convertible

debentures of $69,634, derivative liability of $83,773 and liabilities from discontinued

operations of $6,086,635, whereas our total liabilities at December 31, 2016 consisted of

current liabilities including accounts payable and accrued expenses of $356,005, amounts

due to related parties of $508, convertible debentures of $50,000 and liabilities from

discontinued operations of $5,973,747.

Stockholders’ Deficiency. Our Stockholders’ Deficiency decreased to $(4,954,876)

at March 31, 2017 from $(5,869,425) at December 31, 2016. This decrease was primarily

due to an increase in Common Stock and Additional paid-in capital from the HealthDatix

acquisition during the three months ended March 31, 2017.

THREE MONTHS ENDED MARCH 31, 2017 AS COMPARED TO THREE

MONTHS ENDED MARCH 31, 2017

Revenues and Net Loss. We had $4,350 of revenue from our HealthDatix

subsidiary and a net loss of $242,074 during the three months ended March 31, 2017,

compared to revenue of $0 and a net loss of $238,870 for the three months ended March

31, 2016. The increase in revenue was due primarily to the revenue generated by our

HealthDatix subsidiary acquired in February 2017. In addition to HealthDatix’s

operations, we had a loss from discontinued operations of $(66,937) compared to $(76,333)

for the three months ended March 31, 2017 and March 31, 2016, respectively.

General and Administrative Expenses. General and Administrative Expenses

increased to $167,380 for the three months ended March 31, 2017 from $161,936 for the

three months ended March 31, 2016. For the three months ended March 31, 2017 our

General and Administrative Expenses consisted of corporate administrative expenses of

$40,324, legal and accounting fees of $36,600, employee benefits expenses (health and life

insurance) of $12,665, marketing expenses of $16,666, payroll expenses of $34,483,

consulting expenses of $8,025, commissions and fees expenses of $11,000, and exchange

filing fees of $7,617. For the three months ended March 31, 2016 our General and

Administrative Expenses consisted of corporate administrative expenses of $34,754, legal

and accounting fees of $28,935 employee benefits (health and life insurance) expenses of

$5856, directors and officers insurance expenses of $11,136, payroll expenses of $56,258,

finders fees and commissions expenses of $17,500 and exchange filing fees of $7,500. The

increases from the three months ended March 31, 2016 to the three months ended March

31, 2017 relate primarily due to: (i) an increase in employee benefits expenses; ( (ii) an

increase in marketing expenses; and (iii) an increase in general and administrative costs associated with the operation of our HealthDatix subsidiary. Costs associated with our officers’ salaries and the operation of our HealthDatix subsidiary are expected to increase going forward, as we expand the business operations of HealthDatix which would likely increase our corporate administrative expenses.

Other Income (Expense). We reported interest expense of $11,927 and $601 for

the three months ended March 31, 2017 and March 31, 2016, respectively. Amortization

of debt discount of $457 for the convertible note payable was reported for the three months

ended March 31, 2017.

LIQUIDITY AND CAPITAL RESOURCES

General

As reflected in the accompanying consolidated financial statements, at March 31,

2017, we had $73,527 of cash and stockholders’ deficiency of $(4,954,867). At December

31, 2016, we had $10,522 of cash and stockholders’ deficiency of $(5,869,425).

Our primary capital requirements in 2017 are likely to arise from the expansion of

our HealthDatix operations. It is not possible to quantify those costs at this point in time,

in that they depend on HealthDatix’s business opportunities and the state of the overall

economy. We anticipate raising capital in the private markets to cover any such costs,

though there can be no guaranty we will be able to do so on terms we deem to be acceptable.

We do not have any plans at this point in time to obtain a line of credit or other loan facility

from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s sales

volume, and in our ability to raise additional funds, there can be no assurances that we will

be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the

foreseeable future. We believe we have enough capital to fund our present operations.

Cash Flow Activity

Net cash used in operating activities was $174,715, for the three months ended

March 31, 2017, compared to $282,435 for the three months ended March 31, 2016. Net

cash used in continuing operating activities was $115,740 for the three months ended

March 31, 2017, compared to $12,999 for the three months ended March 31, 2017. Our

primary use of operating cash flows from continuing operating activities was from net

losses of $242,074 and $238,870 for the three months ended March 31, 2017 and 2016,

respectively. Additional contributing factors to the change were from an increase in

accounts receivable of $1,250, decrease in prepaid expenses of $17,492, an increase in

accounts payable and accrued expenses of $18,366, and an increase in accrued interest on

notes payable of $1,801. Net cash used in discontinued operating activities was $8,975 for

the three months ended March 31, 2017 and $269,436 for the three months ended March

31, 2016. Cash used in discontinued operations was primarily from net losses of $66,937 and $76,333 from our ArcMail subsidiary for the three months ended March 31, 2017 and

2016, respectively.

Net cash provided by continuing investing activities was $20,416 for the three months

ended March 31, 2017 and $0 for the three months ended March 31, 2016. For the three

months ended March 31, 2017 the primary source of cash flows from investing activities

was from cash received from the acquisition of our HealthDatix subsidiary. Net cash

provided by discontinued investing activities was $31,636 for the three months ended

March 31, 2017 and $14,946 for the three months ended March 31, 2016.

Net Cash provided by financing activities was $176,500 for the three months ended

March 31, 2017 compared to $160,986 for the three months ended March 31, 2016. The

cash flows provided by continuing financing activities for the three months ended March

31, 2017 was primarily from $100,000 in proceeds from the sale of stock, $100,000 in

proceeds from convertible debentures and $492 in advances from related parties. The cash

flows provided by continuing financing activities for the three months ended March 31,

2016 consisted of amounts due to related parties of $2,300. The cash flows used in

discontinued financing activities for the three months ended March 31, 2017 was $23,992

compared to $158,686 in cash flows provided by discontinued financing activities for the

three months ended March 31, 2016.

Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a

combination of our existing funds and further issuances of securities. Our working capital

requirements are expected to increase in line with the growth of our business. Existing

working capital, further advances and debt instruments, and anticipated cash flow are

expected to be adequate to fund our operations over the next twelve months. We have no

lines of credit or other bank financing arrangements. Generally, we have financed

operations to date through the proceeds of the private placement of equity and debt

instruments. In connection with our business plan, management anticipates additional

increases in operating expenses and capital expenditures relating to: (i) developmental

expenses associated with a start-up business and (ii) marketing expenses. We intend to

finance these expenses with further issuances of securities, and debt issuances. Thereafter,

we expect we will need to raise additional capital and generate revenues to meet long-term

operating requirements. Additional issuances of equity or convertible debt securities will

result in dilution to our current shareholders. Further, such securities might have rights,

preferences or privileges senior to our common stock. Additional financing may not be

available upon acceptable terms, or at all. If adequate funds are not available or are not

available on acceptable terms, we may not be able to take advantage of prospective new

business endeavors or opportunities, which could significantly and materially restrict our

business operations.

Controls and procedures

As filed, 1,924 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief

financial officer, evaluated the effectiveness of our disclosure controls and procedures

pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by

this Quarterly Report on Form 10-Q.

Based on this evaluation, our chief executive officer and chief financial officer

concluded that, as of March 31, 2017, our disclosure controls and procedures are designed

at a reasonable assurance level and are effective to provide reasonable assurance that

information we are required to disclose in reports that we file or submit under the Exchange

Act is recorded, processed, summarized, and reported within the time periods specified in

the SEC’s rules and forms, and that such information is accumulated and communicated to

our management, including our chief executive officer and chief financial officer, as

appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred

during the quarter ended March 31, 2017 that have materially affected, or are reasonably

likely to materially affect, our internal control over financial reporting

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management

recognizes that any controls and procedures, no matter how well designed and operated,

can provide only reasonable assurance of achieving the desired control objectives. In

addition, the design of disclosure controls and procedures must reflect the fact that there

are resource constraints and that management is required to apply its judgment in

evaluating the benefits of possible controls and procedures relative to their costs.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2017-01-01 to 2017-03-31$4.3kus-gaap:SalesRevenueNet
Cost of revenue3 months2017-01-01 to 2017-03-31$180us-gaap:CostOfRevenue
Gross profit3 months2017-01-01 to 2017-03-31$4.2kus-gaap:GrossProfit
Operating income3 months2017-01-01 to 2017-03-31−$163.2kus-gaap:OperatingIncomeLoss
Interest expense3 months2017-01-01 to 2017-03-31−$11.9kus-gaap:InterestExpense
Net income3 months2017-01-01 to 2017-03-31−$242.1kus-gaap:NetIncomeLoss
Diluted EPS3 months2017-01-01 to 2017-03-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2017-01-01 to 2017-03-3148,807,434 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2017-01-01 to 2017-03-31−$124.7kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2017-03-31$73.5kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-03-31$589.2kus-gaap:AssetsCurrent
Total assetsAt period end2017-03-31$1.7mus-gaap:Assets
Current liabilitiesAt period end2017-03-31$6.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-03-31$6.7mus-gaap:Liabilities
Shareholders' equityAt period end2017-03-31−$5.0mus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Source: SEC EDGAR, the filing index for accession 0001211524-17-000068. Last ingested by Listed: Nov 14, 2026, 12:46 ET. Listed shows no prices and gives no investment advice.